Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer

Le, V; Zhong, LX; Narsipur, N; Hays, E; Tran, DK; Rosario, K; Wilson, L

Wilson, L (corresponding author), Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021; 27 (3): 327

Abstract

BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer w......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索